Bone Therapeutics updates data for osteoarthritic knee pain drug clinical trials

BELGIUM – Bone Therapeutics has provided data update for its ongoing clinical studies on enhanced viscosupplement, JTA-004, targeting osteoarthritic knee pain. The JTA-004 Phase III clinical study, having achieved target patient recruitment in December 2020, has now completed the six-month follow-up in all patients. Bone Therapeutics expects to report topline results for the 3-month primary endpoint and 6-month follow-up data in the first half of September 2021. JTA-004 Phase III study is a controlled, randomized, double-blind trial. It is evaluating the potential of a single, intra-articular injection of JTA-004 to…

Read More

Bone Therapeutics secures loan worth €16m from the European Investment Bank

BELGIUM – Bone therapeutics, a cell therapy company that focuses on orthopedic treatment, has signed a loan agreement worth €16m with European Investment Bank (EIB) to bolster its ongoing development and innovation of orthopedic treatment. The EIB loan financing will be disbursed in two tranches of €8 million each, subject to conditions precedent. It will used to support and prepare Bone Therapeutics’ lead asset, the enhanced visco supplement JTA-004 for future regulatory approval and commercialization. JTA-004, is being evaluated in a registrational phase III clinical trial for the treatment of…

Read More